Puma Biotechnology (PBYI) Gains from Sales and Divestitures (2016 - 2026)

Puma Biotechnology has reported Gains from Sales and Divestitures for 11 years, with the latest figure at $471181.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 7.49% year-over-year to $471181.0; the trailing twelve-month figure through Mar 2026 stood at $471181.0 (down 7.49% YoY), and the FY2025 full-year result was $1.2 million, down 10.65% from the prior year.
• Gains from Sales and Divestitures for Q1 2026 stood at $471181.0, down from $1.2 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $1.4 million in Q4 2024, with the low at $189625.0 in Q1 2022.
• Historically, Gains from Sales and Divestitures has averaged $841294.9 across 5 years, with a median of $813333.0 in 2024.
• Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures retreated 20.48% — and 2024, when it jumped 78.61%.
• Puma Biotechnology's Gains from Sales and Divestitures stood at $1.0 million in 2022, then increased by 27.84% to $1.3 million in 2023, then gained by 7.21% to $1.4 million in 2024, then declined by 10.65% to $1.2 million in 2025, then tumbled by 62.19% to $471181.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $471181.0 (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.